The trial enrolled 370 nulliparous individuals, meaning participants who had never carried a pregnancy to term, a group in which IUD insertion is often reported as more uncomfortable. Nulliparity is associated with a narrower cervical canal and a uterus that has not been stretched by previous pregnancy or delivery, both of which are thought to contribute to the discomfort of passing instruments through the cervix and positioning a device inside the cavity. The investigators focused specifically on placements of smaller-diameter IUDs, devices that are commonly chosen for people who have not previously given birth. By concentrating on this population, the study targeted the clinical scenario in which insertion pain is most frequently reported and in which an effective pain-management strategy would have the greatest practical impact.

The intervention itself was straightforward. Participants received an intrauterine instillation of 10 milliliters of mepivacaine at a concentration of 20 milligrams per milliliter, while the comparison group received an instillation of placebo saline in the same volume. Mepivacaine belongs to the amide family of local anesthetics, the same pharmacological class as lidocaine, and works by blocking voltage-gated sodium channels in nerve membranes. When sodium channels are prevented from opening, nociceptive neurons in the uterine wall and cervix cannot generate and propagate the action potentials that carry pain signals toward the spinal cord and brain. Instilling the anesthetic directly into the uterine cavity places the drug in immediate contact with the endometrial surface, where the mechanical stimulation of the insertion process, including tenaculum use, sounding of the cavity, and passage of the insertion tube, activates those pain-sensing fibers.

The route of administration is a key part of why the findings are notable. Existing approaches to insertion pain have included oral analgesics, nonsteroidal anti-inflammatory drugs, intracervical or paracervical nerve blocks, and topical anesthetic gels applied to the cervix, but the evidence supporting many of these measures has been mixed, and some require additional injections or trained personnel to administer. An intrauterine instillation, by contrast, involves introducing a liquid anesthetic through the cervical canal into the cavity itself, a step that can be integrated into the routine preparation for the procedure. The trial’s results indicate that this delivery method achieves sufficient mucosal exposure to blunt pain during the most uncomfortable phases of placement, without the need for injections, specialized equipment, or a change in the basic workflow of the visit.

According to the study’s summary findings, mepivacaine instillation reduced pain during IUD placement compared with placebo saline and improved tolerability of the procedure. Pain during insertion is typically assessed with validated patient-reported scales, and the improvement in tolerability suggests that the benefit extended beyond a numerical pain score to the subjective experience of the procedure as a whole. Tolerability matters clinically in ways that raw pain scores do not always capture. A patient who finds the procedure bearable is more likely to remain still and comfortable during device positioning, which can make the insertion technically easier for the clinician, and is more likely to leave the visit with a positive impression of the method. That impression can influence whether the patient continues with the IUD for its full duration of effectiveness and whether she recommends the method to others.

The public health significance of improving the insertion experience is considerable. IUDs are highly effective, with failure rates far lower than those of oral contraceptives, and they provide years of protection without requiring daily adherence. Professional guidelines in many countries recommend long-acting reversible contraception as a first-line option for a broad range of patients, including adolescents and nulliparous women. Yet surveys and clinical experience consistently show that fear of insertion pain is one of the most commonly cited reasons for hesitancy, and that anticipated pain can influence both the choice to accept an IUD and the counseling conversation that precedes it. A simple, low-risk technique that demonstrably reduces insertion pain addresses one of the last practical objections to a method whose contraceptive performance is otherwise outstanding.

The multicenter design of the trial strengthens the generalizability of the result. By recruiting across multiple sites rather than a single clinic, the investigators reduced the likelihood that their findings reflect the techniques, patient populations, or measurement habits of one particular center. Randomization to mepivacaine or placebo saline, with both groups receiving an identical-appearing instillation, helps control for placebo effects and for the expectation component of procedural pain, which can be substantial. Because both arms underwent the same instillation procedure, the comparison isolates the pharmacological effect of the anesthetic from the mechanical and psychological effects of simply receiving an intervention before insertion.

Mepivacaine itself has a long clinical history in regional and infiltration anesthesia, and its safety profile in other contexts is well characterized. Amide local anesthetics are metabolized in the liver and carry well-understood dose-dependent risks, chiefly central nervous system and cardiovascular toxicity at excessive plasma concentrations. The dose used in the trial, 10 milliliters of a 20 milligram per milliliter solution, corresponds to 200 milligrams of the drug, a quantity consistent with established dosing ranges for local anesthetic use. Instillation into a body cavity also raises the question of systemic absorption through the endometrium, an aspect that the full publication addresses in its safety reporting. The editors’ note accompanying the release directs readers to the article for the complete author list, conflict of interest and financial disclosures, and funding and support information, underscoring the standard transparency expectations for a trial of this kind.

For clinicians, the practical takeaway is that a simple instillation step, performed immediately before insertion, can change the experience of one of the most common gynecological procedures. For patients, particularly those who have never given birth and who are considering an IUD for the first time, the finding offers a concrete reason for optimism that the insertion visit need not be the ordeal that anecdote and online forums often make it out to be. The authors describe mepivacaine instillation as a simple approach that could improve the IUD placement experience, and the trial’s data support that characterization. As with any new procedural practice, adoption will depend on how the technique is incorporated into clinical guidelines, training, and routine counseling, but the underlying result is clear: a few milliliters of local anesthetic, placed where the pain originates, can make IUD placement significantly easier to tolerate.

The study, published in JAMA with the DOI 10.1001/jama.2026.14217, adds a well-controlled data point to an ongoing effort to make contraceptive care less painful and more patient-centered. Pain management during IUD insertion has been the subject of repeated investigation, and this trial distinguishes itself by testing a delivery method that requires no injections and no departure from standard equipment. If the findings are confirmed and adopted broadly, the instillation technique could become a routine part of insertion protocols, particularly for nulliparous patients, closing the gap between the contraceptive effectiveness of the IUD and the comfort of the procedure that provides it.

Subject of Research: Intrauterine mepivacaine instillation for pain relief during IUD placement

Article Title: Intrauterine mepivacaine instillation vs placebo for pain during IUD placement

Article References: Intrauterine mepivacaine instillation vs placebo for pain during IUD placement. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: IUD placement, mepivacaine, local anesthetic, pain management, randomized clinical trial, contraception, nulliparous patients, uterine instillation, JAMA, reproductive health, Intrauterine, instillation